Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Diabetic angiopathies.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Diabetic Angiopathies --- pathology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Diabetic Angiopathies --- Blood Platelets

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Type 2 diabetes (T2DM) is associated with a high cardiovascular risk. Therefore, there is a real need for a preventive treatment to limit the occurrence of cardiovascular complications of T2DM. Thus, drugs that allow a glycemic control and provide a cardio-protective protection are emerging. Indeed, clinical trials have resulted in new drugs associated with a cardiovascular benefit among patients with T2DM who were at high cardiovascular risk: these are inhibitors of co-transporter sodium-glucose type2 (SGLT2) at the renal level with empagliflozin and canagliflozin as well as glucagon-like peptide 1 (GLP-1) analogues with liraglutide and semaglutide. Le diabète de type 2 (DT2) est associé à un risque cardio-vasculaire élevé. Par conséquent, il existe un réel besoin de traitements préventifs pour limiter la survenue des complications-vasculaires du TD2. C’est ainsi que des médicaments qui permettent un contrôle glycémique et qui confèrent une protection cardio-protectrice voient le jour. En effet, des essais cliniques ont abouti à de nouveaux médicaments associés à un bénéfice cardio-vasculaire parmi les patients atteints par le DT2 et qui présentaient un risque cardio-vasculaire élevé : il s’agit des inhibiteurs du cotransporteur sodium-glucose de type 2 (SGLT2) au niveau rénal avec l’empagliflozine et la canagliflozine aonsi que les analogues du glucagon-like-peptide-1 (GLP-1) avec le liraglutide et le semaglutide.

Diabetes Mellitus, Type 2 --- Diabetic Angiopathies --- Cardiovascular Diseases

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Microangiopathies are pathological processes causing degenerative disorders of small vessels. The circulatory problems caused by microangiopathies may be responsible for failure of individual or multiple organs. These pathological processes are indeed one of the most common disorders characterized by high morbility and mortality in the affected patients. Many studies have revealed very complicated processes both at cellular and molecular level. However, much work remains to define the diversity of different pathogenetic mechanisms leading to microangiopathic disorders to provide appropriate prevention and treatment strategies. The aim of this volume is providing illustrative examples of relevant mechanisms responsible for different forms of microangiopathies and how this body of evidences can be harnessed to define new strategies of therapeutic intervention.

Diabetic angiopathies. --- Diabetic vascular complications --- Diabetic vascular diseases --- Blood-vessels --- Diabetes --- Diseases --- Complications --- Endocrinology